{"classes":[{"categories":[{"measurements":[{"comment":"The median was not reached and therefore, the median could not be calculated.","groupId":"OG000","lowerLimit":"84.14","upperLimit":"NA","value":"NA"},{"comment":"The median was not reached and therefore, the median could not be calculated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2061"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"description":"Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.","dispersionType":"95% Confidence Interval","groups":[{"description":"2.5 mg by mouth (p.o.) once daily","id":"OG000","title":"Letrozole"},{"description":"1 mg p.o. once daily","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.","reportingStatus":"POSTED","timeFrame":"84 months","title":"Time to Development of Distant Metastases","type":"SECONDARY","unitOfMeasure":"Months"}